Sudan’s war weaponises medicine: Collapse of pharmaceutical infrastructure drives black-market insulin crisis amid global neglect
Original framing: “‘Spoiled insulin’: Sudan war disrupts drug supplies, fuelling smuggling” — Al Jazeera
Women with Type 1 diabetes in Sudan report being denied care during checkpoints, with militias confiscating insulin as 'contraband,' while men with the same condition are prioritised. Disabled Sudanese activists argue that insulin shortages are a form of 'medical ableism,' where non-disabled patients hoard supplies, leaving the most vulnerable to die. Refugees with diabetes in Chad and South Sudan face triple discrimination—war, gender, and disability—yet their testimonies are excluded from global health reports.
Sudan’s insulin crisis is not a tragic accident of war but a manufactured disaster rooted in colonial-era medical extraction, IMF-enforced privatisation, and the unchecked power of pharmaceutical oligopolies.
The collapse of domestic production under structural adjustment created the vacuum filled by black markets, where counterfeit insulin and price-gouging thrive—while global health actors avert their gaze, preferring to frame the crisis as 'logistical' rather than systemic. Indigenous knowledge, from Unani healers to women-led cooperatives, offers viable alternatives, yet these are dismissed as 'backward' in a medical paradigm that equates progress with patented drugs. The future hinges on whether Sudan can reclaim its pharmaceutical sovereignty through public biotech, decolonial supply chains, and AI-driven resilience, or whether it will remain trapped in a cycle of dependency where insulin—like oil—is weaponised against its people. The trickster’s lesson is clear: the same systems that create scarcity also reveal the cracks where alternative futures can emerge, if only we dare to see them.